Matching articles for "Penmenvy"
Penmenvy — A Second Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • April 14, 2025; (Issue 1726)
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years...
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years old. Penmenvy is the second
pentavalent meningococcal vaccine to become
available in the US; Penbraya was licensed in 2023.